Neoadjuvant Immunotherapy Strategies in HPV-Related Head-and-Neck Cancer.
Neoadjuvant Immunotherapy Strategies in HPV-Related Head-and-Neck Cancer.
复制标题
DOI：
10.1007/s40136-021-00389-9
复制
发表时间：
2022-03
影响因子：
0.6
通讯作者：
Uppaluri, Ravindra
中科院分区：
文献类型：
--
作者：
Saito, Shin;Shibata, Hirofumi;Adkins, Douglas;Uppaluri, Ravindra
在此，我们通过描述已发表的数据和正在进行的临床试验，回顾了HPV相关头颈部鳞状细胞癌（HNSCC）新辅助免疫治疗的当前证据和未来方向。尽管HNSCC在复发性/转移性疾病中显示出对免疫检查点抑制剂的反应，但有限数量的患者受益于这种治疗。人们越来越关注阐明免疫疗法在早期疾病环境（包括初始表现）中的临床获益。HPV相关HNSCC的新辅助免疫治疗是一种合理的方法，因为这些癌症携带强病毒抗原。大多数HPV相关HNSCC患者预后良好，正在评估治疗去强化策略以降低毒性并维持疗效。另一方面，一部分HPV相关HNSCC患者预后较差，需要额外的治疗选择来改善预后。目前正在进行多项临床试验，以评估新辅助免疫疗法是否能实现这些目标。
Herein, we review current evidence and future directions of neoadjuvant immunotherapy in HPV-related head and neck squamous cell carcinoma (HNSCC) by describing published data and ongoing clinical trials. Although HNSCCs have shown response to immune checkpoint inhibitors in recurrent/metastatic disease, a limited number of patients benefit from this treatment. There is an expanding interest in clarifying the clinical benefit of immunotherapy in earlier stage disease setting including at initial presentation. Neoadjuvant immunotherapy for HPV-related HNSCCs represents a rational approach, as these cancers bear strong viral antigens. The majority of patients with HPV-related HNSCC have good prognosis and treatment de-intensification strategies are under evaluation to decrease toxicity and maintain efficacy. On the other hand, a subset of patients with HPV-related HNSCC have a poorer prognosis and additional treatment options are need to improve outcome. Multiple clinical trials are ongoing to evaluate whether neoadjuvant immunotherapy will achieve these goals.